AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5

Sitazit-M 50mg/500mg Tablet

Prescription Icon
Prescription Required

Marketer

Glenmark Pharmaceuticals Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitazit-M 50mg/500mg Tablet

Diabetic patients with type 2 mellitus can manage elevated blood glucose with the dual-action Sitazit-M 50mg/500mg Tablet. This medication mitigates serious diabetic complications, such as vision impairment and nephropathy, and potentially lessens the risk of cardiovascular events like stroke or myocardial infarction. Sitazit-M 50mg/500mg may be administered independently or as an adjunct therapy to existing diabetes treatments. Optimal efficacy is achieved in conjunction with a balanced diet and consistent physical activity. Dosage is individualized based on the patient's health status, glycemic control, and concurrent medications. Consuming the tablet with food minimizes gastrointestinal distress. Consistent daily dosing at the same time maximizes therapeutic benefit; discontinuation should only occur under physician guidance. Adherence to the prescribed diet and exercise regimen is crucial for effective diabetes management; lifestyle modifications are integral to disease control. Commonly reported adverse effects include nausea, vomiting, diarrhea, stomach upset, headache, and pharyngitis. Concurrent use with insulin or sulfonylureas may precipitate hypoglycemia; patients should be aware of its symptoms and management. This medication is not universally appropriate. Prior to commencement, inform your physician of any pre-existing hepatic, renal, or cardiac conditions, pancreatic issues, or excessive alcohol consumption. Pregnant or lactating individuals require medical consultation before initiating treatment. Potential drug interactions necessitate complete disclosure of all medications to your doctor to ensure treatment safety. Alcohol should be minimized due to its potential to exacerbate hypoglycemia. Regular monitoring of renal function and blood glucose levels will be conducted by your doctor throughout treatment.

Uses of Sitazit-M 50mg/500mg Tablet

Managing type 2 diabetes

Major Benefits of Sitazit-M 50mg/500mg Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Sitazit-M 50mg/500mg tablet should be administered with food.

Common Side effects of Sitazit-M 50mg/500mg Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitazit-M 50mg/500mg Tablet:

Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume the Sitazit-M 50mg/500mg tablet with a meal.

How Sitazit-M 50mg/500mg Tablet works:

Sitagliptin and metformin, combined as Sitazit-M 50mg/500mg tablets, offer enhanced blood glucose management. Sitagliptin stimulates increased insulin production by the pancreas, improves insulin utilization, and diminishes hepatic glucose output. Metformin, a biguanide, acts by reducing liver glucose production, slowing intestinal glucose absorption, and enhancing insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining alcohol and Sitazit-M 50mg/500mg tablets is not advisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Sitazit-M 50mg/500mg tablets during pregnancy may pose risks. While human research is limited, animal studies indicate potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Always seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Sitazit-M 50mg/500mg tablets while breastfeeding is likely inadvisable. Available evidence from human studies indicates potential transfer of the medication into breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Sitazit-M 50mg/500mg tablets cautiously, potentially requiring dosage modification. Physician consultation is recommended. This medication is contraindicated for those with severe kidney disease. Regular kidney function monitoring is advised during treatment.

LiverLiverUNSAFE

Patients with liver impairment should not take Sitazit-M 50mg/500mg tablets, as it poses a likely risk. Medical advice is recommended.

What if you forget to take Sitazit-M 50mg/500mg Tablet :

Should you forget to take your Sitazit-M 50mg/500mg Tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sitazit-M 50mg/500mg Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Medication

FAQs on Sitazit-M 50mg/500mg Tablet

Sitazit-M 50mg/500mg tablets combine sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged use of Sitazit-M 50mg/500mg Tablets can lead to vitamin B12 deficiency by hindering its absorption. This deficiency, if left untreated, may result in anemia, neurological issues such as numbness and tingling in the extremities, weakness, urinary problems, cognitive changes, and balance difficulties (ataxia). To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Sitazit-M 50mg/500mg tablets may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Sitazit-M 50mg/500mg Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitazit-M 50mg/500mg tablets with alcohol is unsafe and may raise your risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitagliptin/Metformin (Sitazit-M 50mg/500mg) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect is more likely in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Sitazit-M 50mg/500mg tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitazit-M 50mg/500mg Tablets may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Sitazit-M 50mg/500mg Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitazit-M 50mg/500mg Tablet with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (Sitazit-M 50mg/500mg) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA, Metformin-associated lactic acidosis). This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea/vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Prolonged Sitazit-M 50mg/500mg Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, supplemental vitamin B12 is recommended annually by some researchers.
Store this medication in its original, tightly closed container, as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitazit-M 50mg/500mg tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitazit-M 50mg/500mg tablets may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Patients allergic to Sitazit-M 50mg/500mg Tablet components or excipients, or with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitazit-M 50mg/500mg tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (Sitazit-M 50mg/500mg) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA – Metformin-associated lactic acidosis). This rare side effect necessitates caution in patients with kidney disease, older adults, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Prolonged use of Sitazit-M 50mg/500mg Tablets can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, supplemental vitamin B12 is recommended at least annually.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Sitazit-M 50mg/500mg Tabl...
148